A Senate committee passed a measure to advance the SAFER Banking Act which will now go to a full vote in the chamber and potentially open doors in the cannabis industry.
The US Senate Banking Committee passed a measure on September 27, 2023, to advance the Secure and Fair Enforcement Regulation (SAFER) Banking Act to the senate floor (1). The bill introduced by a bipartisan group of senators, has raised expectations in the cannabis industry which is cash-dependent because they are unable to access regular banking services.
Due to cannabis’s federal illegal status, businesses in the industry are unable to utilize the services a typical “non-cannabis” business is able to use every day. Unfortunately, with several states legalizing cannabis, this does not change the financial aspect for cannabis businesses.
The SAFER Banking Act if passed in the Senate, will allow establishments to have access to normal banking services such as, getting approved for loans, access to deposit accounts, and various other banking services (1).
Stocks for the cannabis industry began to rise following the news. Cronos Group (CRON.TO), SNDL (SNDL.O), and Trulieve Cannabis (TRUL.CD) shares all rose between 1 – 3% (1) after the committee’s vote.
"We are hopeful that the revised language and clearer guidelines for financial institutions will continue to break through the many unproductive hurdles that have prolonged the passage of this bill for far too long," said cannabis firm Acreage Holdings (ACRGau.CD) (1).
The SAFE Banking Act, which was an earlier version of the legislation, was unable to pass a Senate vote even though it passed through the House of Representatives seven times.
"Realizing this first vote out of the Senate signals strong bipartisan support from both chambers of Congress," commented Kim Rivers, CEO of Trulieve (1).
In August 2023 (2), the US Department of Health and Human Services (HHS) formally announced their recommendation to classify cannabis from its original stance as a Schedule I drug to a Schedule III drug. Although their recommendation is not for a full descheduling of the medicinal plant, it is still to be considered a progressive step in the right direction. That decision now falls into the hands of the Drug Enforcement Agency (DEA) who holds the final decision on rescheduling.
It's an exciting time to be in the cannabis industry where everyone will be watching to see how the SAFER Banking Act passes through the Senate.
References
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.